Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
2.910
-0.010 (-0.34%)
At close: Aug 4, 2025, 4:00 PM
2.860
-0.050 (-1.72%)
After-hours: Aug 4, 2025, 5:03 PM EDT
Elevation Oncology Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Elevation Oncology.
Price Target: $0.00 (0.00%)
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Elevation Oncology.
Recommendation Trends
| Rating | Jul '23 | Aug '23 | Sep '23 | Oct '23 | Nov '23 | Dec '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 2 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 1 | 1 | 1 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $0.2 → $15 | Hold → Strong Buy | Upgrades | $0.2 → $15 | +415.46% | Dec 7, 2023 |
| Stifel | Stifel | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +312.37% | Nov 14, 2023 |
| Maxim Group | Maxim Group | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +930.93% | Sep 5, 2023 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $30 | Hold → Strong Buy | Upgrades | $30 | +930.93% | Aug 7, 2023 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 26, 2022 |
Financial Forecast
Revenue This Year
601.80K
from 486.00K
Increased by 23.83%
Revenue Next Year
4.58M
from 601.80K
Increased by 660.39%
EPS This Year
-1.73
from -1.67
EPS Next Year
-1.82
from -1.73
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.9M | 8.9M | 135.8M | ||
| Avg | 601,800 | 4.6M | 101.6M | ||
| Low | n/a | n/a | 68.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 282.5% | 1,376.1% | 2,867.2% | ||
| Avg | 23.8% | 660.4% | 2,119.6% | ||
| Low | - | - | 1,395.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.32 | -1.52 | -0.64 | ||
| Avg | -1.73 | -1.82 | -0.77 | ||
| Low | -2.29 | -2.17 | -0.87 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.